Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

The addition of pertuzumab to neoadjuvant trastuzumab and chemotherapy for women with early-stage, high-risk, HER2+ breast cancer has been observed to lead to higher pathologic complete response rates (pCR), and improved event-free survival compared to trastuzumab and chemotherapy alone. Based on av...

Descripción completa

Detalles Bibliográficos
Autores principales: Rayson, Daniel, Gandhi, Sonal, Joy, Anil A., Brezden-Masley, Christine, Gelmon, Karen A., Sehdev, Sandeep, Cescon, David, Chia, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777307/
https://www.ncbi.nlm.nih.gov/pubmed/36547192
http://dx.doi.org/10.3390/curroncol29120778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777307/
https://www.ncbi.nlm.nih.gov/pubmed/36547192
http://dx.doi.org/10.3390/curroncol29120778

Ejemplares similares